Kava Labs Introduces Kava Swap
Kava Labs™, an open source and non-custodial developer of financial products and services for decentralized finance (DeFi), announced the successful launch of its newest platform project, Kava Swap™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005132/en/
Kava Swap is a cross-chain Autonomous Market Making (AMM) protocol designed to provide an efficient and safe way to swap natively between the world’s largest assets. The new protocol is built on the Kava Platform™ and is backed by low fees, high efficiency, and the ability to generate strong returns for liquidity providers. Kava Swap gives both retail and institutional users access to the over $1 billion of on-chain liquidity on the Kava ecosystem to efficiently trade assets, extend earning opportunities and maximize yields. The new product comes as part of the Kava Mainnet 8 upgrade and has successfully completed a full security audit with CertiK.
“From our inception four years ago, Kava Labs’ mission has been to build a portfolio of decentralized products and services that allow users to gain access to all of the benefits of DeFi, but without the risks present in the current marketplace,” said Scott Stuart, Co-Founder and Head of Products at Kava Labs. “As we expand our ecosystem, Kava continues to deliver on the promise of constructing an open and scalable institutional-grade platform that provides the same level of efficiency, security and ease of use as main street financial products.”
Kava Swap is the third protocol built on the Kava Platform and is an open and permissionless application accessible by anyone, anytime, anywhere in the world. It joins Kava Mint™, which allows users to take out USDX stablecoin loans using their assets as collateral, and Kava Lend™, which allows users to earn rewards by supplying and borrowing assets from money markets. All three protocols come complete with interoperable cross-chain tooling, secure price feeds and institutional-grade safety and reliability. In addition, the Platform’s upgrade to Kava Mainnet 8 will strengthen token holder participation and governance across all applications on the Kava Platform by activating voting on the HARD™ and SWP™ tokens. This gives token investors direct access to governance over the Kava Platform and the Mint Protocol through the KAVA™ token, the Kava Lend Protocol through the HARD token and the Kava Swap Protocol with the SWP token.
“Kava has been focused on developing the safest way for users to grow their cryptocurrency portfolios,” continued Stuart. “We believe that accessing the wealth creating opportunities inside of DeFi does not need to mean increased exposure to risks. Our guiding product principle is to develop an institutional-grade DeFi ecosystem that unlocks the massive growth opportunities available in the crypto marketplace in a de-risked model that helps to evolve our marketplace into the mainstream.”
For more information please visit https://www.kava.io
To Access Kava Swap, please visit: https://app.kava.io
Follow on Twitter:
https://twitter.com/kava_labs
Follow on Telegram:
https://
http://t.me/kavalabs
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005132/en/
Contact information
Martin Allen Frosage
+1.650.489.5124
kava@kava.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients10.5.2024 10:00:00 EEST | Press release
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and who have been through the menopause. NICE confirmed that breast cancer patients who are male and trans, non-binary or intersex may benefit from the test depending on their hormonal profile. The recommendation has the potential to impact more than 3000 additional breast-cancer patients in England who will now have access to the test through the National Health Service (NHS).1 The new guidance expands upon earlier NICE recommendations for testing patients without lymph node involvement. Access to genomic testing for patien
Suzano announces first quarter results and Cerrado Project nears completion10.5.2024 00:30:00 EEST | Press release
Suzano, the world’s largest pulp producer, which celebrates its centenary this year, announces its financial results for the first quarter of 2024 (1Q24). The highlight of the period is the progress of the Cerrado Project, the largest ever capital investment project by the company. The new pulp mill, under construction in the municipality of Ribas do Rio Pardo, Mato Grosso do Sul state, is now 94% complete and will be operational in a few weeks. It will be the largest single-line pulp mill in the world. With a total planned investment of R$22.2 billion, of which R$19.1 billion has been deployed as of the end of April, the new mill will have annual production capacity of 2.55 million tons of pulp, used in the production of sanitary papers and sanitary pads, printing & writing papers and packaging paper, among other items. Given the combined impact of the investment in the construction of the mill and lower pulp prices in recent quarters, Suzano’s US dollar leverage ended the quarter at
John Potthoff Joins RQM+ as CEO9.5.2024 17:00:00 EEST | Press release
RQM+, a leading global MedTech contract research organization (CRO), today announced John Potthoff, Ph.D., as its new CEO. This transition comes as former CEO, Margaret Keegan, announced she plans to move out of day-to-day operations to focus on her role as an operating partner with Linden Capital Partners. Margaret will remain on the board of RQM+. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509890767/en/ John Potthoff (right) joins MedTech leader RQM+ as its new CEO as Margaret Keegan, former CEO, announced her decision to transition to focusing on her role as an operating partner with Linden Capital Partners and will remain on the board of RQM+. (Photo: Business Wire) John, co-founder and former CEO of Elligo Health Research®, has been on the RQM+ board since 2021. He brings extensive MedTech industry expertise to his new role as CEO of RQM+. Prior to Elligo, he was CEO of Theorem Clinical Research, which had a sign
Rigaku Conducts Elemental Analysis of a Sample Obtained by NASA of the Asteroid Bennu9.5.2024 17:00:00 EEST | Press release
Rigaku Corporation, a Rigaku Holdings Group company and Rigaku global solution partner in X-ray analytical equipment (head office: Akishima, Tokyo; president and representative director: Jun Kawakami; hereinafter “Rigaku”), has completed analysis of particles from 101955 Bennu, a near-Earth carbonaceous asteroid classified as a type B. The analysis was performed using ZSX Primus IV, a wavelength dispersive X-ray fluorescence spectrometer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508939191/en/ ZSX Primus IV (Photo: Business Wire) The particles from Bennu are a sample obtained by OSIRIS-Rex, a spacecraft of the United States National Aeronautics and Space Administration (NASA). This analysis constitutes the second time Rigaku has been tasked with conducting analysis related to Bennu. On the first occasion, in December 2023, Rigaku measured water and carbon content in a sample from the carbonaceous asteroid using therm
Wasabi Technologies Delivers Flexible Hybrid Cloud Storage Solutions for Data Protection9.5.2024 16:31:00 EEST | Press release
Wasabi Technologies, the hot cloud storage company, today announced a collaboration with Dell Technologies, via the Extended Technologies Complete program to bring affordable and innovative hybrid cloud solutions for backup, data protection, and long-term retention to customers. In a time marked by the exponential growth of data, organizations worldwide face the need for efficient and cost-effective storage solutions. The Wasabi-Dell collaboration addresses this challenge by providing flexible, efficient hybrid cloud solutions enabling users to optimize their data management processes while simultaneously reducing overall costs. "Dell is a clear industry leader with a broad and deep portfolio of transformative technology,” stated David Friend, co-founder and chief executive officer at Wasabi Technologies. "This collaboration will extend the reach of Wasabi's cloud storage to a broader audience, catering to users in search of a dependable, economical solutions for safeguarding their dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom